Donald McCaffrey
Fortuna: 1 M $ al 31/05/2026
Fortuna: 1 M $ al 31/05/2026
Mr. Donald J.
McCaffrey is a Chairman, President & Chief Executive Officer at Zenith Capital Corp.
(Alberta) and a Chairman, President, CEO & Secretary at Resverlogix Corp.
Mr. McCaffrey also served on the board at Stem Cell Therapeutics Corp.
and ProMIS Neurosciences, Inc.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ZENITH CAPITAL CORP. 4,4 % | 31/03/2026 | 7.027.513 ( 4,4 % ) | 702 751 $ | 31/01/2026 |
RESVERLOGIX CORP. 1,53 % | 02/01/2026 | 5.263.266 ( 1,53 % ) | 384 218 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| RESVERLOGIX CORP. | Director Ejecutivo | 25/04/2003 |
| ZENITH CAPITAL CORP. | Director Ejecutivo | 10/04/2013 |
| Empresas | Cargo | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Miembro de la Junta | 27/03/2006 |
| PROMIS NEUROSCIENCES, INC. | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Resverlogix Corp.
Resverlogix Corp. Pharmaceuticals: MajorHealth Technology Engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases | Health Technology |
Trillium Therapeutics, Inc.
Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Zenith Capital Corp. (Alberta)
Zenith Capital Corp. (Alberta) BiotechnologyHealth Technology Engages in the research and development of biopharmaceuticals | Health Technology |
ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.